Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer
about
(68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and reportPSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical StatusContemporary approaches for imaging skeletal metastasisProstate-specific membrane antigen as a target for cancer imaging and therapyStructure-Activity Relationship of (18)F-Labeled Phosphoramidate Peptidomimetic Prostate-Specific Membrane Antigen (PSMA)-Targeted Inhibitor Analogues for PET Imaging of Prostate CancerPET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challengesTarget Definition in Salvage Radiotherapy for Recurrent Prostate Cancer: The Role of Advanced Molecular ImagingMR-Guided Delivery of Hydrophilic Molecular Imaging Agents Across the Blood-Brain Barrier Through Focused UltrasoundCorrelation of PSMA-Targeted 18F-DCFPyL PET/CT Findings With Immunohistochemical and Genomic Data in a Patient With Metastatic Neuroendocrine Prostate Cancer.Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [68Ga]PSMA I&T and comparison with published data of [68Ga]PSMA HBED-CC.Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with 131I-MIP-1095.Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients.Positron emission tomography (PET) in primary prostate cancer staging and risk assessmentProstate-specific membrane antigen positron emission tomography in prostate cancer: a step toward personalized medicine.An improved synthesis of the radiolabeled prostate-specific membrane antigen inhibitor, [(18) F]DCFPyL.Nanoparticle-Enabled Selective Destruction of Prostate Tumor Using MRI-Guided Focal Photothermal Therapy.PSMA PET/CT with Glu-urea-Lys-(Ahx)-[⁶⁸Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancerPSMA-Based Detection of Prostate Cancer Bone Lesions With ¹⁸F-DCFPyL PET/CT: A Sensitive Alternative to (⁹⁹m)Tc-MDP Bone Scan and Na¹⁸F PET/CT?[(18)F]Fluorobenzoyllysinepentanedioic Acid Carbamates: New Scaffolds for Positron Emission Tomography (PET) Imaging of Prostate-Specific Membrane Antigen (PSMA)Prostate-Specific Membrane Antigen-Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer.Prediction of PSA Progression in Castration-Resistant Prostate Cancer Based on Treatment-Associated Change in Tumor Burden Quantified by 18F-Fluorocholine PET/CT44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617-preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617.[64Cu]XYIMSR-06: A dual-motif CAIX ligand for PET imaging of clear cell renal cell carcinoma.F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients.Synthesis and pre-clinical evaluation of a new class of high-affinity 18F-labeled PSMA ligands for detection of prostate cancer by PET imaging.68Ga-PSMA-11 PET/CT for prostate cancer staging and risk stratification in Chinese patients.Quantitative 18F-fluorocholine positron emission tomography for prostate cancer: correlation between kinetic parameters and Gleason scoring.Multidisciplinary intervention of early, lethal metastatic prostate cancer: Report from the 2015 Coffey-Holden Prostate Cancer Academy Meeting.Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted (18)F-DCFPyL in peripheral ganglia.Prostate Specific Membrane Antigen Targeted 18F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study.Prostate Cancer Imaging with Novel PET Tracers.Small-molecule PSMA ligands. Current state, SAR and perspectives.Current use of PSMA-PET in prostate cancer management.New frontiers in prostate cancer imaging: clinical utility of prostate-specific membrane antigen positron emission tomography.Synthesis and preclinical evaluation of an Al18F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand.[(18)F]Fluoroethyl Triazole Substituted PSMA Inhibitor Exhibiting Rapid Normal Organ Clearance.Addition of PSMA ADC to enzalutamide therapy significantly improves survival in in vivo model of castration resistant prostate cancer.PET imaging of recurrent and metastatic prostate cancer with novel tracers.VPAC1 Targeted (64)Cu-TP3805 Positron Emission Tomography Imaging of Prostate Cancer: Preliminary Evaluation in Man.Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer.
P2860
Q26747480-8E14918F-6CB1-4452-88EF-0BBF66839840Q26774920-BA5A8756-7F5C-453D-ADC9-69970722E6F7Q26798170-B697BF82-C4C1-4FCE-A01C-C50263B50003Q26799439-FE869326-973B-420D-97AE-15437C4C363AQ27705945-CD6EA797-72CD-4269-BFEB-BA2811E97919Q28067404-18C09E18-0C91-4090-84EA-230436206CD8Q28074669-FE47735B-48EE-47E9-88B6-646ED80DA8DEQ28817563-1BA78769-5232-42B7-9CCA-9F541AF8FA15Q31137270-4CD15D4B-53F5-4144-BD11-84CD10C648D4Q31145236-3435C291-B0FF-45ED-8179-5437DBE98B4AQ33581903-9B32B733-1DFD-441C-9693-1C35791E359FQ33841484-50BE6408-D4B0-4D04-B002-294CD886D2D6Q33890153-9D51DDCF-D7C0-4F82-9798-2A642BE541DAQ33914844-A052C920-8B44-400D-B1B8-D97480AE275DQ33917903-8E331C23-86AB-48FB-A2B5-81BABBED26FCQ36023165-52E02D7C-718C-4D5F-9330-82A9F3FBAEBFQ36109230-10E232D9-A08A-48DB-A454-95907B521A83Q36421964-91D9B58B-CB0A-4E49-89FF-2726E0C63DACQ36867784-1A333FF5-9DF6-43ED-A582-912A955E958CQ37390674-E4E3BD2D-D61D-4F8D-933E-7347697FD278Q37496697-6F8C2F9D-B5F0-47B3-8092-A8D647D7AC9EQ37594922-9A9110BE-2D6E-4542-924B-CF76747871D8Q37636649-8DE16062-B876-4410-9E1E-90A53B0774A5Q37662669-373958C0-CF6B-4D53-B609-F2074B647CA2Q37662752-21202854-F57D-4156-8AFE-5AB0AFD61F9AQ37707083-362B949B-5EA9-4D50-99EE-1EC7E4C7AC85Q37714485-315172A1-0F2D-44ED-B50B-682F52872A36Q38610286-062FCB1E-8F0D-410D-BAF2-82E4E12547DCQ38638455-2F8DCC42-6BCB-4371-B934-E569973824C5Q38665724-6D97CEF3-5F61-4F74-99A2-5D8E9F855051Q38732369-8004066C-C43A-4FE5-8375-408ECFAB046EQ38737674-92B6ED08-D217-4484-B293-AA94B1B4B63AQ38744524-D60CBE71-72BA-49BE-859D-A09C6CE698C8Q38757513-9BACBD7A-2490-40C8-98AA-D55DCBD88B6DQ38762963-BB7DB745-5DF4-4105-A3CE-A3C4E1363F27Q38766194-CA6CFA94-3731-4206-8E7F-30AFF33A18B6Q38818338-1B914C65-0DA9-4E82-97D2-7D04486B9098Q38831029-6B2F3BCD-8D9D-446B-82F8-209DCF84595FQ38948710-984568AE-9276-4C1A-96D3-D98B4E0C93E6Q38966705-AFAE312E-6429-4129-B0DF-123AC7A115E4
P2860
Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Initial Evaluation of [(18)F]D ...... PET Imaging of Prostate Cancer
@ast
Initial Evaluation of [(18)F]D ...... PET Imaging of Prostate Cancer
@en
type
label
Initial Evaluation of [(18)F]D ...... PET Imaging of Prostate Cancer
@ast
Initial Evaluation of [(18)F]D ...... PET Imaging of Prostate Cancer
@en
prefLabel
Initial Evaluation of [(18)F]D ...... PET Imaging of Prostate Cancer
@ast
Initial Evaluation of [(18)F]D ...... PET Imaging of Prostate Cancer
@en
P2093
P2860
P1476
Initial Evaluation of [(18)F]D ...... PET Imaging of Prostate Cancer
@en
P2093
Akrita Bhatnagar
Donika Plyku
Emmanuel S Antonarakis
Esther Mena
Mario A Eisenberger
Martin G Pomper
Melin Vranesic
Robert F Dannals
Ronnie C Mease
P2860
P2888
P304
P356
10.1007/S11307-015-0850-8
P577
2015-08-01T00:00:00Z